Prof Kristoffer Hellstrand speaks to ecancer at the 2019 ASH meeting in Orlando about the impact of previous induction chemotherapy in patients with acute myeloid leukaemia (AML).
He explains that this study investigated the effect of immunotherapy in the post-chemotherapy phase, which aims to target residual disease which is the most common cause of relapse and death in these patients.
Prof Hellstrand describes the design of this trial which found that if patients achieved complete remission after one cycle of induction chemotherapy, immunotherapy was efficacious in this population.
He also states that these findings were more pronounced in younger patients, compared to the older population.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content